# Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors

> **NCT02100891** · PHASE2 · TERMINATED · sponsor: **Monica Thakar** · enrollment: 15 (actual)

## Conditions studied

- Ewing Sarcoma
- Neuroblastoma
- Rhabdomyosarcoma
- Osteosarcoma
- CNS Tumors

## Interventions

- **PROCEDURE:** Allogeneic HCT
- **DRUG:** Donor NK Cell Infusion

## Key facts

- **NCT ID:** NCT02100891
- **Lead sponsor:** Monica Thakar
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-03-20
- **Primary completion:** 2020-06-08
- **Final completion:** 2020-07-15
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** 15 patients enrolled out of planned 20, terminated due to slow enrollment at end of study
- **Last updated:** 2025-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02100891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02100891, "Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02100891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*